SUPN Q2 2025 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$165M-1.7% YoY

Gross Profit

$149M89.8% margin

Operating Income

$12M7.3% margin

Net Income

$22M13.6% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

+10.4%

Cash Flow

Operating Cash Flow

$59M

Free Cash Flow

$58M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$319M

Stockholders' Equity

$1.1B

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165M	$168M	-1.7%
Gross Profit	$149M	$150M	-1.2%
Operating Income	$12M	$23M	-46.2%
Net Income	$22M	$20M	+13.0%

Revenue Segments

Product

$158M49%

Qelbree

$78M24%

GOCOVRI

$37M11%

APOKYN

$13M4%

Oxtellar X R

$12M4%

Trokendi Xr

$11M3%

Royalty, License And Other Revenue

$7M2%

Manufactured Product, Other

$7M2%